Researchers from NYU Langone Health and the Perlmutter Cancer Center have made a significant discovery regarding melanoma, identifying a crucial protein known as HOXD13. This transcription factor is essential for the development of blood vessels that nourish tumors with oxygen and nutrients, playing a vital role in cancer progression.
HOXD13 and Tumor Angiogenesis
The findings, published in Cancer Discovery, reveal that HOXD13 activates various biological pathways that enhance blood flow to tumors, a process termed angiogenesis. This includes pathways involving vascular endothelial growth factor (VEGF), semaphorin-3A (SEMA3A), and CD73. Experiments showed that reducing HOXD13 activity led to smaller tumor sizes.
Effects on Immune Response
The team also found that melanoma patients with elevated HOXD13 levels had reduced numbers of cytotoxic T cells, which are crucial for targeting and eliminating cancer cells. Furthermore, T cells struggled to penetrate tumors in individuals with high HOXD13 activity.
"Our research underscores the role of HOXD13 as a significant driver of melanoma and its ability to inhibit T cell functions necessary for combating the disease," stated Pietro Berico, PhD, the study's lead investigator.
Creating an Immune Barrier
Further investigation indicated that HOXD13 modifies the tumor microenvironment, diminishing immune responses. It elevates CD73 levels, leading to increased adenosine, which acts as a shield for tumors by impeding T cell movement into cancerous tissues. When HOXD13 was inhibited, T cells were more successful in infiltrating tumors.
"Our findings support the idea of targeting both angiogenesis and adenosine-receptor pathways as a novel therapeutic strategy for melanoma driven by HOXD13," added Eva Hernando-Monge, PhD, a senior investigator in the study.
Exploring Combination Therapies
Hernando-Monge highlighted that clinical trials are currently assessing drugs that inhibit VEGF and adenosine receptors in melanoma and other cancers. Some of these trials are exploring combinations with immunotherapy, which harnesses the immune system to fight cancer.
If successful, the research team aims to investigate combination treatments using both VEGF and adenosine-receptor inhibitors for patients exhibiting high HOXD13 levels.
The team also plans to explore whether these pathways can be targeted in other cancers characterized by elevated HOXD13, including certain glioblastomas, sarcomas, and osteosarcomas.
Collaborative Research Efforts
This groundbreaking study analyzed tumor samples from over 200 melanoma patients across the U.S., Brazil, and Mexico, pinpointing active biological pathways. HOXD13 emerged as a pivotal factor. Additional experiments in mice and human melanoma cell lines corroborated its role in promoting blood vessel growth and evading immune detection.
The research was supported by multiple National Institutes of Health grants and additional funding sources, showcasing a collaborative effort involving numerous contributors from NYU Langone and partner institutions.